Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment.
Lobetti-Bodoni C
Mech Ageing Dev. 2012 Jun 9;133(7):479-88. doi: 10.1016/j.mad.2012.05.007
The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia.
De Filippi P
Pediatr Blood Cancer. 2011 Dec 19;59(3):580-2. doi: 10.1002/pbc.23401
Phase II study of sorafenib in patients with relapsed or refractory lymphoma.
Guidetti A
Br J Haematol. 2012 May 10;158(1):108-19. doi: 10.1111/j.1365-2141.2012.09139.x
Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways.
Tassi E
Clin Cancer Res. 2012 May 2;18(12):3316-27. doi: 10.1158/1078-0432.CCR-11-2232
Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.
Zappasodi R
Blood. 2011 Aug 22;118(16):4421-30. doi: 10.1182/blood-2011-06-364570
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.
Guidetti A
Cancer. 2011 May 12;117(22):5074-84. doi: 10.1002/cncr.26182
Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.
Servida F
Invest New Drugs. 2010 Jul 8;29(6):1264-75. doi: 10.1007/s10637-010-9475-6
Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.
Zappasodi R
Cancer Res. 2010 Sep 30;70(22):9062-72. doi: 10.1158/0008-5472.CAN-10-1825
Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.
Viviani S
Leuk Lymphoma. 51(7):1251-9. doi: 10.3109/10428194.2010.486090
Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature.
Lavazza C
Blood. 2010 Jan 14;115(11):2231-40. doi: 10.1182/blood-2009-08-239632